Real-life Second-line Epirubicin-Paclitaxel Regimen as Treatment of Relapsed Small-Cell Lung Cancer : EpiTax Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 29
- 试验地点
- 3
- 主要终点
- Progression-free survival
研究概览
简要总结
Initial chemosensitivity is known concerning SCLC but relapse is almost systematic, especially at a metastatic stage. Brain metastasis are identified around 40 to 50% during the evolution of the disease. Concerning the efficacy of epirubicin combined with paclitaxel from the second-line treatment, data is lacking more particularly about specific response on brain metastasis.
In this retrospective multicentric observational study in real life conditions, we try to evaluate systemic and specific cerebral efficacy and safety of a regimen combining epirubicin and paclitaxel in patients treated between 2010 and 2020 for a small cell lung carcinoma from the second-line treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults (age ≥18 years)
- •Histologically or cytologically SCLC diagnosis
- •Treated with epirubicin-paclitaxel doublet between January 2010 and December 2020
排除标准
- •Opposition to participate registered
- •Patients under legal protection
- •Patients afflicted by another subtype of lung carcinomas
- •SCLC not treated with the epirubicin-paclitaxel doublet
结局指标
主要结局
Progression-free survival
时间窗: through study completion, an average of 1 year
Time from epirubicin-paclitaxel regimen initiation to disease progression (according to Response Evaluation Criteria In Solid Tumors v1.1) or death from any cause
次要结局
- Overall survival(1 year)
- Objective response rate(1 year)
- Intracranial control rate(1 year)
- Disease control rate(1 year)
- Toxicities(1 year)